Sun Pharma-Organon deal: HDFC target raised to Rs 2,030

Stock action after Organon announcement

Sun Pharmaceutical Industries Ltd shares were trading flat on Tuesday, after a sharp move in the previous session. On Monday, the stock gained 7.03% and closed at Rs 1,733.80 on the BSE after the company signed an agreement to acquire US-based Organon & Co. The rise also came as multiple brokerages turned more constructive on the stock following the deal announcement. Reports in the same news flow said the rally took the stock close to its all-time high of Rs 1,851.20, hit on May 2. Another market update noted the stock was up nearly 8% intraday to INR 1,742, and was trading around INR 1,736.10 at 1012 IST.

What Sun Pharma is buying

Sun Pharma has entered into a definitive agreement to acquire Organon in an all-cash transaction. The transaction values Organon at an enterprise valuation of USD 11,750 million. Sun Pharma would acquire 100% of Organon’s shares at USD 14 per share, translating to a total equity value of roughly USD 3,990 million. Post-merger, Organon is expected to be delisted from the New York Stock Exchange, according to brokerage commentary cited in the reports. The deal is expected to close in early 2027.

Funding plan and balance sheet shift

Funding details outlined in the coverage indicate a mix of internal resources and debt. Sun Pharma is expected to finance USD 2,000 to USD 2,500 million through internal accruals and raise USD 1,500 to USD 2,000 million through debt. Another account of the company’s plan said the acquisition will be funded using available cash resources and bank loans. HDFC Securities also noted that Sun Pharma would move from being a net cash company, holding USD 3,200 million as of December 2025, to a net debt position of approximately USD 8,000 million.

Why HDFC Securities kept a ‘Buy’ rating

HDFC Securities maintained a positive stance on Sun Pharma and reiterated a ‘Buy’ call, raising its target price to Rs 2,030 from Rs 2,000. In its note, the brokerage said the acquisition provides immediate and substantial scale, while adding that execution priorities remain important. It highlighted “growth revival in established brands, cross leverage of Sun's branded generic business, and sustaining growth in Innovative Medicine business with focus on cross-selling and in-licensing” as key.

HDFC Securities also said the buyout would expand Sun Pharma’s innovative medicine portfolio, pushing its share to 27% by FY26E. The brokerage highlighted entry into Women’s Health, referencing USD 1,750 million in sales and brands such as Nexplanon, and said this diversifies the portfolio beyond dermatology and ophthalmology. It also noted access to a USD 691 million biosimilar business and a stronger foothold in China with established generic and biosimilar products.

Expected synergies and accretion metrics

On synergy estimates, HDFC Securities expects the combined entity to generate cost synergies of over USD 350 million within the next two to four years. The brokerage further expects the deal to be “sales/EBITDA/PAT accretive by 80%/82%/27% in FY28.” It also attributed the relatively lower earnings growth to higher interest costs and depreciation.

Separate brokerage commentary in the same news flow said analysts project the acquisition could nearly double Sun Pharma’s annual revenue to approximately USD 12,400 million and increase EBITDA to around USD 3,700 million. Another broker note cited in the coverage also pointed to Organon’s annual free cash flow of USD 1,000 million and stable EBITDA margins as supportive for the combined financial profile.

Company commentary and strategic direction

In a conference call mentioned in the reports, Sun Pharma said it will leverage Organon’s biosimilar portfolio and sees potential growth for the segment in India. Sun Pharma’s Executive Chairman Dilip Shanghvi was quoted as saying the deal would strengthen the company’s platform, adding that Organon’s portfolio, capabilities and global reach are complementary and could create a stronger, more diversified platform.

Another explainer in the news flow said Organon was spun off from Merck & Co. in 2021 and carries debt of USD 8,600 million. It also reported a 5% fall in quarterly revenue and a net loss of USD 205 million, which adds context to the integration challenge for the acquirer.

What other brokerages are saying on targets

Beyond HDFC Securities’ Rs 2,030 target, the coverage cited other updated targets and “Buy” calls. One brokerage maintained a ‘Buy’ rating with a target price of Rs 2,025. Nuvama maintained ‘Buy’ with a revised target of Rs 2,000 versus Rs 1,875. Another note referenced a ‘Buy’ rating with a target price of Rs 1,968. Citi reiterated ‘Buy’ with a target price of Rs 2,180, and Jefferies maintained ‘Buy’ with a target of Rs 2,070.

A separate snapshot attributed to S&P Global Market Intelligence said 37 analysts’ average target price is ₹1,974.49, with a high of ₹2,450 and a low of ₹1,475, and stated that 77.78% of analysts recommend a ‘BUY’ rating.

Key numbers at a glance

What to watch until closing

The transaction is expected to close in early 2027, making regulatory approvals and integration planning key near-term milestones. Investors are also likely to track how leverage evolves, given the shift from USD 3,200 million net cash (December 2025) to around USD 8,000 million net debt as flagged by HDFC Securities. Organon’s delisting from the NYSE is expected after closing, as per the brokerage note.

Conclusion

Sun Pharma’s Organon agreement has triggered a sharp stock move and a round of target upgrades, with HDFC Securities lifting its target to Rs 2,030 while reiterating a ‘Buy’. The next concrete checkpoints remain the financing execution, progress toward an early-2027 close, and clarity on delivering the stated USD 350 million-plus cost synergies within two to four years.